Sym004 in SCCHN Patients Failing Anti-EGFR Based Therapy
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
The trial is designed as a multi-center, open label Phase 2 trial that investigates the
efficacy and safety of Sym004 in subjects with squamous cell cancer of the head and neck
(SCCHN). Subjects included must have responded to previous anti-epidermal growth factor
receptor (anti-EGFR) monoclonal antibody-based therapy and subsequently become resistant to
that therapy. It is believed that Sym004 has the potential to induce tumor responses and
provide a superior treatment option to subjects with advanced SCCHN.
Symphogen was the sponsor for planning/conducting and reporting results for this trial.